Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis
Author:
Publisher
Elsevier BV
Subject
Radiology Nuclear Medicine and imaging,Oncology,General Medicine
Reference28 articles.
1. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group;Giaccone;J Clin Oncol,1998
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N Engl J Med,1996
3. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer;Holmes;J Natl Cancer Inst,1991
4. Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer;Yeh;Oncology,2005
5. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma;Lin;Anticancer Drugs,2007
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles;PLOS Biology;2023-10-26
2. Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer;Nanomedicine: Nanotechnology, Biology and Medicine;2023-04
3. Comparison of one-week versus three-week paclitaxel for advanced pan-carcinomas: systematic review and meta-analysis;Aging;2022-02-26
4. Development, validation, and application of an UPLC-MS/MS method for vancomycin, norvancomycin, methotrexate, paclitaxel, and imatinib analysis in human plasma;Annals of Clinical Biochemistry: International Journal of Laboratory Medicine;2022-02-24
5. The impact of SBF2 on taxane-induced peripheral neuropathy;PLOS Genetics;2022-01-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3